Earnings call transcript: KP Tissue Q1 2026 beats EPS forecast, stock dips

KP Tissue delivered a solid Q1 2026 beat on profitability, with adjusted EBITDA up 14.6% YoY to CAD 86.9 million and net income up 28.6% to CAD 19.8 million, while revenue slipped 0.3% to CAD 544.6 million and missed forecasts. Margin improved to 16.0% from 13.9% on lower pulp and warehousing costs, and management reaffirmed late-2028 startup timing for the western U.S. TAD project. Despite the earnings strength, shares fell 1.74% pre-market as the company flagged rising freight, fuel, and other input-cost pressures.

Analysis

The setup here is less about the quarter itself and more about the next two cost curves: fiber and fuel. The company is effectively demonstrating that it can defend margin even with flat-to-down top line by squeezing logistics, insourcing, and mix, but that also means the next leg of earnings depends on whether commodity inflation stays local or becomes broad-based. If pulp, freight, and oil all move together, the margin expansion is not scalable; if they stay dislocated, the stock can keep re-rating because the market is still discounting the durability of the improvement.

The underappreciated second-order effect is capacity optionality. Memphis plus the western U.S. TAD project gives them a path to win share without having to buy it with discounting, which is structurally better than chasing volume in a soft category. That also makes them more interesting as a regional supply-chain beneficiary: tighter U.S. capacity and better service levels can matter more than modest changes in category demand, especially if competitors are slower to add premium capacity.

The market may be underestimating how much of the “good quarter” is actually a forward signal for pricing power rather than just cost relief. Management is clearly telling you that pricing is a last resort, not the first response, which usually means they are willing to let volume wobble before sacrificing margin. That is bullish for earnings quality over the next 1-2 quarters, but it also raises the risk of a sharper step-up in pricing later if the cost basket keeps rising, which could invite volume elasticity and a more volatile second half.

Contrarian takeaway: the move is probably not overdone on fundamentals, but it may be overdone on timing. The real catalyst is not the earnings beat; it’s whether they can turn the next 60-90 days of input inflation into a clean, broad-based price action without breaking share. If they can’t, the stock can consolidate despite strong optics; if they can, the market will start treating this as a self-help compounder with multiple expansion potential.

Key Decisions for Investors

• KPT.TO: Buy the pullback over the next 1-2 trading sessions; target a 10-15% upside over 3-6 months if margin stays near current levels and pricing remains deferred. Stop if management signals category-driven volume deterioration or pricing resistance in Canada.
• KPT.TO: Add a call spread for 3-6 months out to express upside from margin durability and Memphis/TAD optionality; attractive if implied vol stays muted and the stock remains near highs. Risk/reward is favorable because the downside is defined while the catalyst window is tied to Q2-Q3 commodity commentary.
• Pair trade: long KPT.TO / short a more commodity-levered consumer packaging or tissue peer with weaker balance sheet and less insourcing flexibility over 2-4 months. The thesis is that KPT can preserve EBITDA through a cost shock better than peers that need volume discounting.
• Monitor NVDA only as a sentiment read-through on China policy risk, not as a direct fundamental link; if the market starts pricing more trade-policy easing broadly, cyclicals with China-exposed supply chains could benefit. Use any broad risk-on into semis as an opportunity to add to KPT rather than chase the move.
• Avoid shorting on the headline beat alone; wait for evidence that Q2/Q3 input costs are being absorbed without pricing. The risk to a short is that cost inflation catalyzes a price action before volume data turns, forcing a higher-margin reset than the market expects.